Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Curcumin and fish oil tested to shrink Smokers' lung nodules

NCT ID NCT03598309

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a combination of curcumin (from turmeric) and fish oil can reduce the size of lung nodules in former and current smokers aged 55 and older. Nineteen participants took the supplements or a placebo for 6 months. The study aims to see if the nodules shrink and if the treatment is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Curcumin C3 Complex and Omega-3-Acid Ethyl Esters (fish oil)
What this could lead to
If it works, this could point toward a way to reduce lung nodules in smokers, potentially lowering cancer risk.
What could go wrong
This is a very small, early-phase trial with only 19 participants. The results may not apply to everyone, and the supplements might not shrink nodules or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

19 people

The number who actually took part.

Started

Jun 2019

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, 55 years of age or older * Former smokers and current enrolled in LDCT lung cancer screening or those who are detected using a regular CT, and have Lung-RADS 3 category lesion(s), that would get a 6 month f/u LDCT or regular CT based on Lung-RADS recommendations or former and current smokers enrolled in LDCT lung cancer screening, or regular CT and have Lung-RADS 2 category lesions with part-solid or non-solid lung nodule ≥4mm mean diameter detected during screening LDCT or regular CT scans * History of cigarette smoking with ≥ 20 pack years * All current smokers should accept to receive smoking cessation * Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1 * Able to swallow study pills * Able to undergo CT * Not allergic to components of study agents * Willing to discontinue current vitamin/mineral supplement use containing components of study agents. A standard multivitamin supplement provided for the study * Willing to comply with proposed visit and treatment schedule * Able to understand and willing to sign a written informed consent document * Participants must have normal organ and marrow function * Willing to use contraception during the intervention period of 6 months (males and females) * Not pregnant or lactating nor planning to become pregnant or lactate during the 6 month study intervention period.. Exclusion Criteria: * Invasive cancer diagnosis (excluding basal cell carcinoma or skin squamous cell carcinoma) diagnosed within the last 2 years * Inability to undergo CT * Newly diagnosed nodule meeting Lung-RADS 4 criteria * Have taken doxycycline or tetracycline less than or equal to 2 weeks * Females- pregnant or lactating (throughout the duration of intervention of 6 months) * Unwilling to use effective form of birth control (Males and females) (throughout the duration of intervention of 6 months).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer, protection against are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.